Navigation Links
Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer
Date:6/11/2008

either safety or efficacy in future trials. These and other risks and uncertainties are described in the reports and other documents filed by Oncothyreon Inc. with the SEC and/or Canadian regulatory authorities.

Although Oncothyreon believes that any forward-looking statements contained herein are reasonable, it can give no assurance that its expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of the risks and uncertainties associated with Oncothyreon, you are encouraged to review the official corporate documents filed by Oncothyreon Inc. with the securities regulators in United States and Canada with the SEC and on SEDAR. Oncothyreon is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Additional Information

Additional information relating to Oncothyreon can be found on U.S. EDGAR at http://www.sec.gov and on SEDAR at http://www.sedar.com.


'/>"/>
SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncothyreon to receive milestone payment
2. Oncothyreon Reports First Quarter 2008 Financial Results
3. Oncothyreon files investigational new drug application for PX-866 oncology compound
4. Data for Oncothyreons PX-12 and PX-866 presented at AACR Annual Meeting
5. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
6. Oncothyreon announces effectiveness of shelf registration statement
7. Oncothyreon announces issuance of patent for PX-867
8. Oncothyreon to present at upcoming investment conferences
9. Oncothyreon reports full year and fourth quarter 2007 financial results
10. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
11. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015 /PRNewswire/ - Portage ... Exchange: PBT.U), and Biohaven Pharmaceutical Holding Company Limited ... a Phase I study of BHV-0223, a glutamate ... (IND) regarding BHV-0223 and recently obtained clearance from ... proceed with human testing. Portage holds 54% equity ...
(Date:8/27/2015)... Aug. 27, 2015 HUYA Bioscience International (HUYA) today ... the Japan Society of HTLV-1, held this week at ... purpose of the Society is to promote research on ... of medical technology and research related to these fields ... "HUYA is proud to support this prestigious conference," ...
(Date:8/27/2015)... 27, 2015 In response to recent ... and The US Postal Service to no longer ... ,select agents, by the CDC, Marken reaffirmed today ... sensitive shipments. Marken uses its flexible ... and certified personnel to ensure the safe and ...
(Date:8/26/2015)... 26, 2015  Roka Bioscience, Inc. (NASDAQ: ROKA ... testing solutions for the detection of foodborne pathogens, today ... the Sidoti & Company Emerging Growth Conference on September ... at the New York Marriott Marquis. ... through the investor relations section of Roka Bioscience,s website ...
Breaking Biology Technology:Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4Marken Ensures Safe Transportation Of Select Agents And Toxins 2
... Nov. 15 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President,and ... ONCY), will present a,corporate overview of the company ... The event is being held at the National ... About Oncolytics Biotech Inc. Oncolytics is a ...
... Pitch for,U-Md. Bioscience Day, COLLEGE PARK, Md., Nov. ... new technology enabling him to develop an,infinite variety of ... of,venture capitalists and the title of "Best Inventor Pitch" ... the university,s Office of Technology Commercialization,the College of Chemical ...
... Stock Exchange Symbol: MS, EDMONTON, Nov. 14 ... developer in the treatment of multiple sclerosis (MS), ... quarter, ended,September 30, 2007. "During the quarter, ... our lead drug, MBP8298, for the treatment of ...
Cached Biology Technology:Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society 2Pure Plastics Pitch Proves Perfect 2Pure Plastics Pitch Proves Perfect 3BioMS Medical announces third quarter 2007 results 2BioMS Medical announces third quarter 2007 results 3BioMS Medical announces third quarter 2007 results 4
(Date:8/5/2015)... The biosensors market is proving highly attractive ... newer sectors, and development of devices resulting in higher ... seen the entry of multiple participants each year with ... (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) Recent ... Global Biosensors Market ( http://www.frost.com/nee9 ), finds that ...
(Date:8/3/2015)... Calif. , Aug. 3, 2015 Synaptics, ... human interface solutions, today announced that members of the ... at the Pacific Crest Global Technology Leadership Forum on ... The conference will be held at the Sonnenalp Resort ... The presentation may include forward-looking information. An audio ...
(Date:7/31/2015)... julho de 2015 A 10 a. ... realizada pela BGI de 22-25 de outubro de 2015, em ... A conferência está celebrando seu 10 o. aniversário este ... tornou uma das reuniões mais influentes do mundo no ... dinâmicos, entusiastas e prazerosos. A ICG-10 ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... think may be a basic recipe for capturing and ... from essentially any mammal, including cows, pigs and even ... issue of the journal Cell , a Cell ... work in mice earlier this year, which includes inhibitory ...
... of Rochester have shown that the human brainonce thought ... to allow us to make the best decisions possible ... published in today,s issue of the journal Neuron ... 2002 Nobel Prize for their 1979 research that argued ...
... Research Institute scientists, along with colleagues from the University ... to deliver one of those research raritiesan unmitigated success. ... remarkable accuracy, predicts how bacterial proteins fold and interact. ... in this week,s Early Edition of the Proceedings ...
Cached Biology News:Recipe for capturing authentic embryonic stem cells may apply to any mammal, study suggests 2Recipe for capturing authentic embryonic stem cells may apply to any mammal, study suggests 3Our unconscious brain makes the best decisions possible 2Our unconscious brain makes the best decisions possible 3New technique is quantum leap forward in understanding proteins 2New technique is quantum leap forward in understanding proteins 3New technique is quantum leap forward in understanding proteins 4
Component in MasterPure™ Purification Kits...
...
Tris-EDTA Buffer Solution, 1X, pH 8.0, sterile...
Human Cell Line Slides...
Biology Products: